Details of the Drug
General Information of Drug (ID: DMZON3T)
Drug Name |
(2s)-Pyrrolidin-2-Ylmethylamine
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
(S)-pyrrolidin-2-ylmethanamine; 69500-64-7; (S)-(+)-2-(Aminomethyl)pyrrolidine; (2S)-PYRROLIDIN-2-YLMETHYLAMINE; (S)-2-(Aminomethyl)pyrrolidine; (S)-2-aminomethylpyrrolidine; (S)-pyrrolidin-2-ylmethylamine; [(2S)-pyrrolidin-2-yl]methanamine; 1-[(2S)-pyrrolidin-2-yl]methanamine; 2-Pyrrolidinemethanamine, (2S)-; (S)-(+)-2-(Aminomethyl)pyrrolidine, 98%; AC1MC09B; SCHEMBL83314; CHEBI:44632; CTK5D0186; (2S)-pyrrolidin-2-ylmethanamine; MolPort-003-932-494; AUKXFNABVHIUAC-YFKPBYRVSA-N; (2S)-Pyrrolidin-2-yl-methylamine; ZINC39357503
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 100.16 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | -0.6 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 1 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 2 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 2 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||